Villanueva-Meyer J, Leonard M H, Briscoe E, Cesani F, Ali S A, Rhoden S, Hove M, Cowan D
Department of Radiology, University of Texas Medical Branch, Galveston 77555-0793, USA.
J Nucl Med. 1996 Jun;37(6):926-30.
Our goal was to determine the clinical usefulness of 99mTc-sestamibi to identify breast cancer in patients prior to biopsy.
We studied 66 patients who received 20 mCi 99mTc-sestamibi intravenously. Lateral and anterior planar images were gathered within 30 min of the injection. Only focal increased uptake was interpreted as positive. Confirmatory pathologic diagnoses were obtained within 2 mo. The prevalence of breast cancer in our sample was 54%.
We report an overall sensitivity of 83% and specificity of 93% for the diagnosis of breast cancer. In palpable lesions, the sensitivity was of 94% with a specificity of 91%, while in nonpalpable abnormalities the sensitivity was of 64% with a 100% specificity. Six patients with a malignancy had negative scans, four of these lesions were nonpalpable. Only two of 31 patients with benign lesions had an abnormal scan.
Mammoscintigraphy with 99mTc-sestamibi has high specificity and adequate sensitivity for the noninvasive diagnosis of breast carcinomas.
我们的目标是确定99mTc-司他米比在活检前患者中识别乳腺癌的临床效用。
我们研究了66例静脉注射20mCi 99mTc-司他米比的患者。在注射后30分钟内采集侧位和前位平面图像。仅将局灶性摄取增加解释为阳性。在2个月内获得确诊的病理诊断。我们样本中乳腺癌的患病率为54%。
我们报告乳腺癌诊断的总体敏感性为83%，特异性为93%。在可触及病变中，敏感性为94%，特异性为91%，而在不可触及异常中，敏感性为64%，特异性为100%。6例恶性肿瘤患者扫描结果为阴性，其中4个病变不可触及。31例良性病变患者中只有2例扫描异常。
99mTc-司他米比乳腺闪烁显像对乳腺癌的无创诊断具有高特异性和足够的敏感性。
